Table 3.
Comparison of outcomes when the first quit attempt uses 100 % varenicline versus the current market mix of interventions (multiple quit attempts per patient over a lifetime)
| Outcomes | Market mix | Varenicline net |
|---|---|---|
| Incidence of smoking-related diseases | ||
| COPD | 0.26 | −0.01 |
| Lung cancer | 0.11 | −0.01 |
| MI | 0.07 | −0.0003 |
| Stroke | 0.17 | −0.005 |
| Stomach cancer | 0.08 | −0.0006 |
| Hepatic cancer | 0.04 | 0.0001 |
| Abstinence time, years | 11.19 | 4.56 |
| Life-years | 29.30 | 0.25 |
| Discounted QALYs | 14.96 | 0.08 |
| Discounted costs (¥) | ||
| Smoking-related disease | 3,316,453 | −357,587 |
| Direct medical total | 3,379,894 | −206,095 |
| Indirect (lost wages) | 6,148,085 | −246,814 |
| Total costs | 9,527,979 | −452,909 |
Results for the market mix scenario are presented in absolute terms, while results for varenicline are presented as the difference from the market mix strategy
¥ Japanese yen, COPD chronic obstructive pulmonary disease, MI myocardial infarction, QALYs quality-adjusted life-years